In our database, we identified 73 patients with advanced driver gene (exon 19 deletion, L858R, ALK‐rearrangement) mutant NSCLC treated with targeted therapy (targeted therapy only group) and 18 that were treated with targeted therapy followed by SS (targeted therapy plus SS group). This evidence concerns the gene ALK and non-small cell lung carcinoma.